

Appendix 1: VIN 2/3 and VaIN 2/3 Lesions from Datasets of HPV-007, 013, and 015 (125126/-(b)(4)-, submitted 2/6/08)

VIN 2/3 cases which occurred in control subjects, combined datasets for studies HPV-007, 013, and 015 (CBER generated)

Control-VIN 2/3 or worse							
AN/Study	Sero	Pap baseline	PCR M0, 7	PCR other times	PCR Lesion	Path	Visits with Dx
24704/011	18=14 6=10	Neg (1/4/03)	M0-Neg. M7-Neg.		+16, 6	VIN 2/3 (8/9/05)	M30
31339/012	Negative	Negative (2/4/03)	M0-Neg. M7Neg.		+16	VIN 2/3 (6/11/04)	M12
30894/012	Negative	Negative (10/24/02)	M0: +58	Vax 2: +58 Postvax 3: +58 M12: +16	+16	VIN 2/3 (10/21/04)	M24
48976/015	Negative	Negative (2/6/03)	M0: negative	M 12: +16	+16	VIN 2/3 (9/16/03)	Postvax 3
57658/015	Negative	Negative (5/9/03)	M0: negative	M12: +16, 56	+6, 16 +16, 56	VIN 2/3 (11/2/05) (12/7/04)	M24 M24
57668/015	Negative	Negative (5/23/03)	M0: Negative		+16	VIN 2/3 (4/14/05)	M12
42767/015	Negative	Negative (11/13/02)	M0: Negative	M24: +56	+6, 31	VIN 2/3 (9/1/04)	M12
47147/015	Negative	Negative (1/17/03)	M0: Negative	M24: +52	+16	VIN 2/3 (2/23/05)	M24
42126/015	Negative	Negative (10/29/02)	M0: Negative	Negative	+6, 16, 31	VIN 2/3 (4/10/04)	M24
45919/015	Negative	Negative (12/26/02)	M0: Negative	Negative	+16 +16, 58	VIN 2/3 (5/31/05) (7/12/05)	M 24
31106/012	Negative	Negative (10/18/02)	M0- +51 M7- +16		+11,16,39	VIN 2/3 (4/12/04)	M18
30058/012	Negative	Negative (8/6/02)	M0-Neg. M7-+16	M12- +16,18, 31	+16,18, 31 +16 +16 +16, 51, 56 +16, 56	VIN 2/3 (4/12/04) (7/30/04) EGL 1 EGL 2 EGL 3 EGL 4	M18 M24
24572/011/18 (018)	Negative	Negative	M0- Negative M7- Negative	M36-+16	+16		M48 9/19/06 – EGL 2
31904/012/20 (033)	Negative	Negative	M0-+51	M24-+6, 18, 51 M30-+6 M36-+6, 16, 59		+16 +16,59	M48 10/6/06 – EGL 1 EGL 2

VIN 2/3 cases which occurred in control subjects, combined datasets for studies HPV-007, 013, and 015 (CBER generated) [CONT]

Control-VIN 2/3 or worse (cont.)							
AN/Study/Age	Sero	Pap baseline	PCR M0, 7	PCR other times	PCR Lesion	Path	Visits with Dx
32541/012/21 (041)	Negative	Negative	M0-Negative M7-Negative	M30-+16 M36-+16	+16		M48 1/31/07 – EGL 1
43024/015/18 (041)	Negative	Negative	M0-+39, 51		+6, 16, 56 +16, 52		M36 10/25/05 – EGL1 7/19/06- EGL 1
55453/015/18 (60)	16+	Unsatisfactory (Negative @ Vax 2)	M0-+16, 31	M12-+6, 16 (bx EGL 2) M48-+16, 33, 39, 51, 52 (cer bx)		+6	M12 8/24/04 – EGL 1
41924/015	Negative	Negative	M0: +39, 52	Postvax 3: +16, 18	+16	VIN 2/3 (10/23/03)	M12
56691/015	Negative	Negative (3/6/03)	M0: Negative	Postvax 3: +6, 16	+16	VIN 2/3 (11/23/03)	Postvax 3
41112/015	Negative	Negative (10/21/02)	M0: Negative	Postvax 3: + 11, 16, 18	+16	VIN 2/3 (1/13/05)	M24
47444/015	Negative	Unsat. (1/22/03 & 2/19/03) Negative (3/5/03)	M0: +53, 56	Postvax 3: +16 M24: + 16	+16	VIN 2/3 (2/23/05)	M24
47626/015	Negative	Negative (1/28/03)	M0: +58	Postvax 3: +16 M24: +16	+16	VIN 2/3 (1/21/04)	M12
7105/007	Negative	Negative (10/11/00)	M0: Negative	Postvax 3: +16 M12, 18, 24, 30, 36: +16	+16	VIN 2/3 (8/5/02)	M18
30204/012	Negative	Negative (10/31/02)	M0: +52	Vax 2: +52 Postvax 3: +11, 16, 52 M12: +11, 16	+16 +16	VIN 2/3 (3/24/05) (12/2/05)	M30 M36
40760/015	Negative	Negative (10/7/02)	M0: negative	Postvax 3: + 11, 16	+11, 16	VIN 2/3 (9/22/03)	M12

VIN 2/3 cases which occurred in control subjects, combined datasets for studies HPV-007, 013, and 015 (CBER generated) [CONT]

Control-VIN 2/3 or worse (cont.)							
AN/Study/Age	Sero	Pap baseline	PCR M0, 7	PCR other times	PCR Lesion	Path	Visits with Dx
33361/012	+6, 16	LSIL (2/17/03)	M0: +6, 52	Vax 2: +6, 52 Postvax 3: +16, 51, 52, 58, 59 M12: +16, 31, 58 M30: +59	+31, 58 +31, 56, 59 +16 +16, 51 +16	VIN 2/3 (1/13/05) (6/3/05) (6/29/06- EGL 1) (9/19/06- EGL 1) (9/19/06- EGL 2)	M18 M24 M48
44187/015	Negative	Negative (11/27/02)	M0: +16	M12: +6, 16	+16	VIN 2/3 (6/25/03)	Postvax 3
24100/011	Negative	ASCUS+ (10/28/02)	M0-+58, 6 M7-+6		+6, 31,	VIN 2/3 (12/2/03)	M12
25278/011	+6, 16	Neg. (3/7/03)	M0-+16, 33, 6 M7-+6, 16		+16, 33	VIN 2/3 (8/2/04) (12/19/04)	M12 M18
40069/015	Negative	Reactive (10/15/02) Negative (5/14/03)	M0: +6, 39, 52, 58		+6 +52	VIN 2/3 (5/28/03) (2/28/04)	Postvax 3 M12
24448/011/22 (018)	+16	Negative	M0- Negative M7- Negative	M36-+11		+16, 56	M48 8/17/06- EGL 1
25350/011	Negative	Neg (3/10/03)	M0-Neg M7-Neg.		+31	VIN 2/3 (11/22/04)	M19
30754/012	Negative	Negative (11/21/02)	M0: Negative	M 36: +6, 31	+31	VIN 2/3 (6/14/06)	M36
55623/015	Negative	Negative (2/21/03)	M0: +31		+31 +31	VaIN 2/3 (11/29/03) (1/20/04)	Postvax 3
55196/015	+18	Negative (2/21/03)	M0: +18	M24: 6, 39, 58 M36: +31, 35	Negative	VIN 2/3 (8/11/04)	M12
42562/015	6=9	Negative (11/6/02)	M0: Negative	Postvax 3: +6, 11, 16 M24: +6 M36: +35, 52, 58	Negative	VIN 2/3 (10/27/05)	M36
44580/015	Negative	Negative (12/11/02)	M0: Negative	Negative	Negative	VIN 2/3 (2/10/04)	M12

Source: From datasets labbx.xpt, labxpcr 1-13.xpt, labxpap 1-5.xpt, sero1-2.xpt, study HPV-007, 013, and 015; **Bolded numbers:** Subjects naïve through Month 7 (sero- and PCR negative at baseline, and PCR negative at Month 7 for relevant vaccine HPV type at baseline); *Italic numbers:* Subjects naïve at baseline (sero- and PCR-negative for relevant vaccine HPV type); **Numbers highlighted in yellow:** Lesions in

subjects infected with relevant HPV type at baseline; **Numbers highlighted in teal:** Lesions in subjects naïve (PCR negative) for relevant non-vaccine HPV type associated with lesion.

Numbers highlighted in green: Subjects with lesions negative for any of the 14 HPV types tested (regardless of baseline sero- and/or PCR status).

*Cases noted – HPV 16 detected by M7, subjects Naïve for HPV 11 or HPV 18 through Month 7)

VIN 2/3 cases or worse which occurred in Gardasil subjects, combined datasets for studies HPV-007, 013, and 015 (CBER generated)

Gardasil-VIN 2/3 or worse							
AN/Study/Age	Sero	Pap baseline	PCR M0, 7	PCR other times	PCR Lesion	Path	Visits with Dx
32024/012/18 (32)	Negative	Negative	M0- Negative Vax 2- +16,31 M7-+16, 31 M12-+16, 31 M18-+16, 31 M24-+16, 31 M30-+16, 31 M36-+16, 31 M48-+31		+16		M36 (4/19/06)- EGL 1&2
30018/012	Negative	Negative (7/9/02)	M0: +16	Vax2:+16 Postvax3: +16 M12: +16	+16	VIN 2/3 (2/15/04)	M19
57189/015	11=19 6=14	LSIL (3/10/03)	M0: +6, 16, 51	Postvax 3: + 6, 16	+6, 16	VIN 2/3 (3/14/05)	M12
56504/015	+6, 11	LSIL (3/1/03)	M0: +11, 16, 51, 35, 56	Postvax 3: +11, 16, 31 M24: + 35	+16, 35	VIN 2/3 (2/18/04)	M12
54842/015	+16	HSIL (2/24/03)	M0: +16	Postvax 3: + 16	+16 +16	VIN 2/3 (3/25/03) (4/28/03)	Vax 1
24911/011/22 (016)	+16	Negative	M0-+16 Vax 2- +16 M7-+16		+16		M18 (8/4/04)- EGL 1
24817/011/23 (018)	Negative (6=9)	Negative	M0-+16 Vax 2- +6, 16 M7-+16	M18-+16,51	+16, 51		M12 (6/14/04)- EGL 1

VIN 2/3 cases which occurred in Gardasil subjects, combined datasets for studies HPV-007, 013, and 015 (CBER generated) [CONT]

Gardasil-VIN 2/3 or worse (cont.)							
AN/Study/Age	Sero	Pap baseline	PCR M0, 7	PCR other times	PCR Lesion	Path	Visits with Dx
33684/012/18 (009)	6+ (11=11, 18=11)	Negative	M0-+16, 31, 39, 52 Vax 2- +16, 31 M7-+16, 31, 52	M12-+16, 31		+16	Vax 2 (5/8/03)-EGL 1
33904/012 monovalent	+18	ASC-H (3/14/03)	M0: +16	Vax 1: +16 Vax 2: +16, 18	+16	VIN 2/3 (7/31/03)	Vax 2
42878/015	+16	Negative (2/4/03)	M0: Negative	Postvax 3: +18	+45 +33	VIN 2/3 (2/8/05) (9/27/05)	M24
32202/012	Negative	Negative (1/22/03)	M0: +39, 52	Vax2: +52 M12: +59 M18: +58	+33, 58, 59	VIN 2/3 (1/29/04)	M12
25202/011	+16	Negative (3/1/03)	Negative		+51	VIN 2/3 (9/21/04)	M19
24717/011/17 (015)	Negative	ASC-US+	M0-+6, 45, 51 Vax 2 - +6, 31 M7-+6	M12-+6	+56		M18 (7/13/04)-EGL 2
31675/012/19 (32)	11, 16+ (6=10)	Negative	M0-+51,59 Vax 2- +16, 59 M7-+16, 59	M18-+16, 59 M24-+16, 52 M30-+52 M36-+16, 35, 52 M48-+16, 35	+35		M48 (8/18/06)-EGL 1
33362/012/19 (058)	negative	Negative	M0- negative M7- Negative	M24-+56 M30-+31, 56 M36-+31	+31		M48 (8/8/06)-EGL 1
30928/012	+16	LSIL (10/19/02)	M0: +31, 33, 39, 51	Vax 1: +31	Negative	VIN 2/3 (10/19/02)	Prevax
32808/012	Negative	LSIL (1/28/03)	M0: +16	Vax 1: +16 Vax 2: +16 Postvax 3: +16	Negative	VIN 2/3 (3/2/04)	M12

VIN 2/3 cases which occurred in Gardasil subjects, combined datasets for studies HPV-007, 013, and 015 (CBER generated) [CONT]

Gardasil-VIN 2/3 or worse (cont.)							
AN/Study/Age	Sero	Pap baseline	PCR M0, 7	PCR other times	PCR Lesion	Path	Visits with Dx
32363/012	Negative	Negative (9/3/03)	M0: Negative		Negative	VIN 2/3 (12/8/05)	M30
44061/015	Negative	Unsat. (12/14/02) Negative (1/3/03)	M0: +59		Negative	VIN 2/3 (9/13/03)	Postvax 3
56399/015/21 (012)	Negative	Negative	M0-+6, 16 M7-+6, 16		Negative		M12 (3/18/04)- EGL 1
33082/-12/20 (23)	Negative	Negative	M0- Negative M7- Negative	Negative	No HPV	Well-differentiated anogenital cancer	M24

Source: From datasets labbx.xpt, labxpcr 1-13.xpt, labxpap 1-5.xpt, sero1-2.xpt, study HPV-007, 013, and 015;

Key

Bolded numbers: Subjects naïve through Month 7 (sero- and PCR negative at baseline, and PCR negative at Month 7 for relevant vaccine HPV type at baseline).

Italic numbers: Subjects naïve at baseline (sero- and PCR-negative for relevant vaccine HPV type)

Numbers highlighted in yellow: Lesions in subjects infected with relevant HPV type at baseline.

Numbers highlighted in teal: Lesions in subjects naïve (PCR negative) for relevant non-vaccine HPV type associated with lesion.

Numbers highlighted in green: Subjects with lesions negative for any of the 14 HPV types tested (regardless of baseline sero- and/or PCR status).

*Cases noted – HPV 16 detected by M7, subjects Naïve for HPV 11 or HPV 18 through Month 7)

VaIN 2/3 cases which occurred in Control subjects, combined datasets for studies HPV-007, 013, and 015 (CBER generated)

Control-VaIN 2/3							
AN/Study/Age	Sero	Pap baseline	PCR M0, 7	PCR other times	PCR Lesion	Path	Visits with Dx
24735/011	6=9	LSIL (1/10/03)	M0: +52, 59	M19: +18, 31	+18, 31	VaIN 2/3 (7/27/04)	M19
31672/012	Negative	Negative (11/21/02)	M0: Negative	M18: +52 M 24: +52 M30: +52, 6 M36: +6	+6	VaIN 2/3 (2/27/06)	M36
32076/012	Negative	Negative (12/6/02)	M0: Negative	M24: +35 M 30: +16, 35, 58 M36: +58	+16, 35	VaIN 2/3 (6/22/05)	M30
41946/015	Negative	Negative (10/28/02)	M0: Negative	M36: +16	+16	VaIN 2/3 (6/7/05)	M24
42358/015	Negative	Negative (11/21/02)	M0: Negative		+16, 51	VaIN 2/3 (6/8/04)	M12
55616/015	16=16	Unsat (2/21/03) Negative (4/10/03)	M0: Negative	Postvax 3: +18	+16, 56	VaIN 2/3 (10/5/05)	M24
31022/012	Negative	ASC-US (-) (10/17/02)	M0: Negative		+16, 56	VaIN 2/3 (5/30/05)	M30
33019/012	Negative	Negative (2/6/03)	M0: Negative	M12: +11, 16, 18, 59, 58, 56 M18: +58 M24: +58 M30: +58, 59	+58 +16, 56 +16, 56	VaIN 2/3 (6/13/05) (9/11/06- vag bx 1 vag bx 2)	M24 M48
30408/012/18 (009)	Negative	Negative	M0- Negative M7- Negative	M24-+59 M30-+59 M36-+59 M48-+16	+16		M48 9/22/06- vag bx 1
49220/015/17 (69)	Negative	Negative	M0- Negative M7- Negative		+16		M24 10/6/05- vag bx 2
55554/015	Negative	Negative (2/21/03)	M0: Negative	Postvax 3: +16 M24: +16, 51	+16	VaIN 2/3 (6/1/04)	M12
25120/011	Negative	LSIL (2/28/03)	M0: +33, 39, 59	Vax 2: +6, 16, 18	+33 +18	VaIN 2/3 (4/1/03) (4/6/05)	Vax 1 M 24

VaIN 2/3 cases which occurred in Control subjects, combined datasets for studies HPV-007, 013, and 015 (CBER generated) [CONT]

Control-VaIN 2/3 (cont.)							
AN/Study/Age	Sero	Pap baseline	PCR M0, 7	PCR other times	PCR Lesion	Path	Visits with Dx
25278/011	+6, 16	Negative (3/7/03)	M0: +6, 16, 33	Vax 2: +6, 16 Postvax 3: +16 M12: +16, 33, 56	+16, 33, 56 +16, 33	VaIN 2/3 (7/8/04) (12/9/04)	M12 M18
56323/015	Negative	Unsat (2/27/03) LSIL (4/10/03)	M0: +16	Postvax 3: +16, 59	+16 +16	VaIN 2/3 (6/25/03) (7/21/03)	Vax 2 Vax 2
32575/012	18=12	LSIL (1/9/03)	M0: +52	Postvax 3: +52	+52 Negative	VaIN 2/3 (2/26/03) (10/15/03)	Vax 1 Postvax 3
24142/011	Negative	Negative (10/29/02)	Negative		+31	VaIN 2/3 (12/16/04)	M24
49111/015	Negative	LSIL (2/7/03)	M0: +33, 56		+56 +51	VaIN 2/3 (7/14/03) (10/6/04)	Vax 2 M12
31534/012	Negative	Negative (11/13/02)	M0: +18, 31, 39, 35	Vax 2: +18, 31, 35 Postvax 3: +18, 31, 35 M12: +18, 31, 35 M18: +18, 35, 56 M24: +18, 35, 56 M30&36: +35	+35	VaIN 2/3 (12/15/04)	M24

VaIN 2/3 cases which occurred in Control subjects, combined datasets for studies HPV-007, 013, and 015 (CBER generated) [CONT]

Control-VaIN 2/3 (cont.)							
AN/Study/Age	Sero	Pap baseline	PCR M0, 7	PCR other times	PCR Lesion	Path	Visits with Dx
32915/012	6=13	Negative (1/28/03)	M0: +52	Postvax 3: +59	Negative	VaIN 2/3 (9/7/04)	M18
30716/012	6=12	Negative (9/19/02)	M0: +56		Negative	VaIN 2/3 (10/25/05)	M36
31722/012	Negative	Negative (11/18/02)	M0: Negative		Negative	VaIN 2/3 (1/17/06)	M36
49397/015	+6	ASC-H (2/10/03)	M0: +6, 16, 18 M7: +6, 16, 18	M 24: +16	Negative	VaIN 2/3 11/28/03	Postvax 3
31606/012/19 (058)	Negative	Negative	M0- Negative M7- Negative		Negative		M48 7/17/06- vag bx 1
31866/012/18 (058)	Negative	Negative	M0- Negative M7: +16, 31	M12: +56, 59 M24: +45 M30: +35	Negative		M48 8/8/06- vag bx 1
32798/012/22 (058)	Negative (6=11)	Negative	M0- Negative Vax 2: +16	M24: +52 M30: +52 M36: +45, 52 M48: +35, 45, 52, 6	Negative		M48 7/25/06- vag bx 1
44137/015/21 (041)	Negative	Negative	M0: +52 M7- Negative	M12: +16	Negative		M48 3/21/07- vag bx 1

Source: From datasets labbx.xpt, labxpcr 1-13.xpt, labxpap 1-5.xpt, sero1-2.xpt, study HPV-007, 013, and 015.

Key

Bolded numbers: Subjects naïve through Month 7 (sero- and PCR negative at baseline, and PCR negative at Month 7 for relevant vaccine HPV type at baseline).

Italic numbers: Subjects naïve at baseline (sero- and PCR-negative for relevant vaccine HPV type)

Numbers highlighted in yellow: Lesions in subjects infected with relevant HPV type at baseline.

Numbers highlighted in teal: Lesions in subjects naïve (PCR negative) for relevant non-vaccine HPV type associated with lesion.

Numbers highlighted in green: Subjects with lesions negative for any of the 14 HPV types tested (regardless of baseline sero- and/or PCR status).

*Cases noted – HPV 16 detected by M7, subjects Naïve for HPV 11 or HPV 18 through Month 7)

VaIN 2/3 cases which occurred in Gardasil subjects, combined datasets for studies HPV-007, 013, and 015 (CBER generated)

Gardasil-VaIN 2/3							
AN/Study/Age	Sero	Pap baseline	PCR M0, 7	PCR other times	PCR Lesion	Path	Visits with Dx
43062/015	+16	LSIL (11/11/02)	M0: +16, 18, 45, 51, 59, 35	Postvax 3: +16, 18, 51 M12: +18, 59	+18, 33, 56, 58	VaIN 2/3 (10/19/04)	M24
56504/015	+6, 11	LSIL (3/1/03)	M0: +11, 16, 51, 35		+16, 31 +16, 35	VaIN 2/3 (12/1/03) (2/18/04)	Postvax 3 M12
32447/012 monovalent	Negative	Negative (12/28/02)	M0: +16, 31	Vax 2: +16, 31 Postvax 3: +16, 31 M12: +16 M24: +39	+16	VaIN 2/3 (3/7/04)	M12
20414/011	Negative	Negative (9/26/02)	M0: +59	M30 and M36: +59	+59 +59	VaIN 2/3 (10/26/04) (4/25/05)	M19 M24
30111/012	Negative	LSIL (8/28/02)	M0: Negative	Vax 2: +51 Postvax 3: +16, 45 M 12: +16, 45 M30: +51, 39	+51	VaIN 2/3 (5/25/05)	M30
30976/012	Negative	Negative (10/10/02)	M0: Negative	M24: +52, 58 M30: +52, 58 36: +52, 58	+52, 58	VaIN 2/3 (1/19/06)	M36
32043/012	Negative	Negative (12/05/02)	M0: Negative	Negative	+58	VaIN 2/3 (5/22/06)	M48
31991/012	+16	Negative (12/2/02)	M0: +16	Vax 2: +16 Postvax 3: +16 M24: +52	+31, 59	VaIN 2/3 (6/30/05)	M30
57710/015	16=15 +6	Negative (4/28/03)	M0: Negative		+56	VaIN 2/3 (2/7/06)	M24
48713/015	Negative	Negative (2/4/03)	M0: +51	M12: 39, 52	+52 Negative	VaIN 2/3 (7/31/04) (2/19/05)	M12 M24
48079/015	Negative	LSIL (2/4/03)	M0: +16, 51	M12: +16, 31, 51, 59	+52, 59	VaIN 2/3 (10/19/04)	M12

VaIN 2/3 cases which occurred in Gardasil subjects, combined datasets for studies HPV-007, 013, and 015 (CBER generated) [CONT]

Gardasil VAIN 2/3 (cont)							
AN/Study/Age	Sero	Pap baseline	PCR M0, 7	PCR other times	PCR Lesion	Path	Visits with Dx
31487/012/18 (050)	Negative	Negative	M0- Negative M7- Negative	M18-+51,52 M24-+52,56 M30-+39, 52 M36-+52 M48-+52	+52		M36 1/16/06- vag bx 1
33362/012/19 (058)	Negative	Negative	M0- Negative M7- Negative	M24-+56 M30-+31,56 M36-+31 M48-+31	+31		M48 8/8/06- vag bx 1
47402/015/23 (073)	+18	HSIL	M0-+18, 39, 59		+31		M48 (10/7/06- vag bx
30629/012	18-15 6-9	Negative (9/8/02)	M0: Negative	Negative	Negative	VaIN 2/3 (4/25/05)	M30

Key

Bolded numbers: Subjects naïve through Month 7 (sero- and PCR negative at baseline, and PCR negative at Month 7 for relevant vaccine HPV type at baseline).

Italic numbers: Subjects naïve at baseline (sero- and PCR-negative for relevant vaccine HPV type)

Numbers highlighted in yellow: Lesions in subjects infected with relevant HPV type at baseline.

Numbers highlighted in teal: Lesions in subjects naïve (PCR negative) for relevant non-vaccine HPV type associated with lesion.

Numbers highlighted in green: Subjects with lesions negative for any of the 14 HPV types tested (regardless of baseline sero- and/or PCR status).

Source: From datasets labbx.xpt, labxpcr 1-13.xpt, labxpap 1-5.xpt, sero1-2.xpt, study HPV-007, 013, and 015.